BioInvent International AB (CHIX:BINVS) Cyclically Adjusted Revenue per Share: kr0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BINVS BioInvent International AB CHIX:BINVS
39 GF Score
Price kr34.75
GF Value kr69.82
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Cyclically Adjusted Revenue per Share?

BioInvent International AB CHIX:BINVS 39 Cyclically Adjusted Revenue per Share is kr0.00 as of Jun. 2026. GuruFocus rates CHIX:BINVS with a GF Score™ of 39/100 and a GF Value™ of kr69.82. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioInvent International AB's adjusted revenue per share for the three months ended in Jun. 2026 was kr0.194. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, BioInvent International AB's average Cyclically Adjusted Revenue Growth Rate was -13.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -18.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -18.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of BioInvent International AB was -13.20% per year. The lowest was -22.30% per year. And the median was -18.15% per year.

As of today (2026-08-27), BioInvent International AB's current stock price is kr34.75. BioInvent International AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr0.00. BioInvent International AB's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioInvent International AB was 11.53. The lowest was 1.57. And the median was 3.86.


BioInvent International AB  (CHIX:BINVs) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioInvent International AB was 11.53. The lowest was 1.57. And the median was 3.86.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioInvent International AB Cyclically Adjusted Revenue per Share Related Terms


BioInvent International AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioInvent International AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB Cyclically Adjusted Revenue per Share Chart

BioInvent International AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.60 8.52 10.26 3.86 5.07

BioInvent International AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.57 5.52 5.07 5.83 0.00

CHIX:BINVS vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, BioInvent International AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Cyclically Adjusted PS Ratio falls into.


CHIX:BINVS
39GF Score
BioInvent International AB CHIX:BINVS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioInvent International AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioInvent International AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.194/134.6100*134.6100
=0.194

Current CPI (Jun. 2026) = 134.6100.

BioInvent International AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.070 101.138 0.093
201612 2.788 102.022 3.679
201703 0.996 102.022 1.314
201706 0.949 102.752 1.243
201709 0.571 103.279 0.744
201712 1.098 103.793 1.424
201803 0.894 103.962 1.158
201806 0.668 104.875 0.857
201809 0.464 105.679 0.591
201812 0.723 105.912 0.919
201903 1.231 105.886 1.565
201906 1.724 106.742 2.174
201909 0.851 107.214 1.068
201912 1.234 107.766 1.541
202003 0.835 106.563 1.055
202006 0.796 107.498 0.997
202009 0.495 107.635 0.619
202012 2.508 108.296 3.117
202103 0.151 108.360 0.188
202106 0.090 108.928 0.111
202109 0.051 110.338 0.062
202112 0.084 112.486 0.101
202203 0.285 114.825 0.334
202206 4.627 118.384 5.261
202209 0.276 122.296 0.304
202212 0.318 126.365 0.339
202303 0.247 127.042 0.262
202306 0.199 129.407 0.207
202309 0.407 130.224 0.421
202312 0.233 131.912 0.238
202403 0.090 132.205 0.092
202406 0.070 132.716 0.071
202409 0.194 132.304 0.197
202412 0.325 132.987 0.329
202503 0.335 132.825 0.340
202506 3.012 133.699 3.033
202509 0.051 133.480 0.051
202512 0.046 133.390 0.046
202603 0.204 133.560 0.206
202606 0.194 134.610 0.194

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr0.00 mean?
BioInvent International AB (CHIX:BINVS) has a Cyclically Adjusted Revenue per Share of kr0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioInvent International AB and its competitors.
Is BioInvent International AB's Cyclically Adjusted Revenue per Share too high?
BioInvent International AB's current Cyclically Adjusted Revenue per Share is kr0.00. Overall, BioInvent International AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
BioInvent International AB's Cyclically Adjusted Revenue per Share of kr0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Cyclically Adjusted Revenue per Share is kr0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (CHIX:BINVS) has a current Cyclically Adjusted Revenue per Share of kr0.00. The stock's GF Value™ is kr69.82, compared to a current price of kr34.75 — trading 50.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr0.00. BioInvent International AB's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioInvent International AB (CHIX:BINVS), the current Cyclically Adjusted Revenue per Share is kr0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioInvent International AB (CHIX:BINVS) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of kr34.75 is trading 50.2% below its estimated GF Value™ of kr69.82.

Key valuation signals for CHIX:BINVS:

  • Cyclically Adjusted Revenue per Share: kr0.00
  • GF Value™: kr69.82 vs. price of kr34.75 (50.2% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the CHIX:BINVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioInvent International AB Business Description

Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
39GF Score

Get the complete analysis for CHIX:BINVS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.75
Price
kr69.82
GF Value